The Company's Personal Brain Health Tracking Technology to be Trialed by
With over 13,000 employees, MS&AD Insurance Group Holdings, Inc. is a leading global insurance organization that engages in the management of its group companies, which are
As a progressive platform for risk solutions, MS&AD has a goal of utilizing advanced digital technology to enhance healthcare services that lead to better health as well as preventing and detecting diseases in their early stages in order to prevent serious illness. Using ICA technology allows MS&AD to offer measurement of brain performance, which can highlight issues at an early stage when they can be more easily addressed as part of their proactive approach to customer health. The pilot deployment has been enabled by
MSP Life and MSA Life expect to make the necessary preparations to deploy the ICA technology to their customers as soon as its utility has been confirmed through the
Dr.
OptiMind is an ICA powered application that uses smartphones to quickly and sensitively measure cognitive function. Based on Cognetivity's patented ICA platform, the app uses a rapid visual classification test to measure brain performance, and can incorporate measurements of lifestyle habits such as sleep and amount of exercise to give lifestyle recommendations to optimize users' brain health. This system is useful not only for the elderly who are concerned about potential cognitive decline, but also for adults who would like to take control of their brain health and maximize their brain's performance in their day to day lives. The ICA was initially developed by Cognetivity as medical software, in the form of the FDA registered and CE marked CognICATM application, to help diagnose neurological issues such as dementia at an early stage. However, the practicality and usefulness of the test allows it to be used in a variety of situations where the ability to quickly and accurately measure brain function over time can improve lives and reduce risk.
Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity's CognICATM uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. CognICATM is currently available for clinical use in the
ON BEHALF OF THE BOARD
"Sina Habibi"
Chief Executive Officer and Director
FORWARD-LOOKING STATEMENTS:
Certain statements included in this news release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "assume" "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
SOURCE
© Canada Newswire, source